This application seeks continued funding for a period of five years for the Cancer Center Support Grant of the University of Southern California Comprehensive Cancer Center. The USC Comprehensive Cancer Center is a separately defined component of the USC School of Medicine. The Center pursues excellence in cancer research, treatment and education through collaborative relationships among its members and with the community. The Cancer Center Program is divided into three divisions, each with a number of program areas; Basic Research; Clinical Investigations; and Cancer Cause and Prevention. The objective of the basic research program areas is to promote interdisciplinary studies on the causes and mechanisms of cancer development and spread through research in virology, cell and molecular biology, chemical carcinogenesis, experimental immunology, and cancer pharmacology, The clinical programs conduct research on effective new methods for cancer diagnosis and management and aim to provide the best possible care for cancer patients at the Norris Cancer Hospital, the LAC-USC Medical Center, the Childrens Hospital of Los Angeles, and the other hospitals affiliated with the Center. The programs in cancer cause and prevention conduct hypothesis based studies of the occurrence of cancer in human populations; develop and apply statistical methods to improve the quality of epidemiological studies and clinical trials; and to design and carry out multidisciplinary studies of methods of cancer prevention, cancer screening, treatment compliance, and patient adaptations to cancer and its treatment. The Cancer Center also actively promotes the education and training of basic scientists, clinicians, clinical investigators, and allied health personnel who deal with cancer. Funds are requested to support the senior leadership, the program coordinators, the administration, the shared facilities and resources, and the continued development of USC Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014089-13
Application #
3101374
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1980-04-01
Project End
1990-11-30
Budget Start
1988-02-19
Budget End
1988-11-30
Support Year
13
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications